Neuberger Berman Group
IMVT icon

Neuberger Berman Group’s Immunovant IMVT Stock Holding History

Neuberger Berman Group’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-87,440
Closed -$3.68M – 1874
2023
Q4 		$3.68M Buy
87,440
+35,618
+69% +$1.31M ﹤0.01% 1120
2023
Q3 		$1.99M Sell
51,822
-25,965
-33% -$587K ﹤0.01% 1081
2023
Q2 		$1.48M Buy
+77,787
New +$1.45M ﹤0.01% 1151

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Neuberger Berman Group's IMVT Position: Q1 2024 in Review

Neuberger Berman Group sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 87,440 shares — an estimated $3.68M sold.

Neuberger Berman Group first reported a position in IMVT in Q2 2023 and held it in 3 quarters. The position peaked at $3.68M in Q4 2023. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

  • Neuberger Berman Group reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
  • Neuberger Berman Group sold 87,440 Immunovant shares in Q1 2024, an estimated $3.68M.
  • Neuberger Berman Group first reported a position in Immunovant in Q2 2023 and held it in 3 quarters.
  • Neuberger Berman Group's Immunovant position peaked at $3.68M in Q4 2023.
  • 209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Neuberger Berman Group's 13F filing for Q1 2024, filed 13 May 2024.